The IGF1/IGF1R inhibitor linsitinib preferentially targets YTHDF2-expressing cells, inhibiting GSC viability without affecting normal neural stem cells (NSCs) or impairing glioblastoma growth in vivo (82). This evidence concerns the gene YTHDF2 and glioblastoma.